Ascites in patients with hepatocellular carcinoma: Prevalence, associated factors, prognostic impact, and staging strategy

Hepatology International

Volumn 7, Issue 1, 2013, Pages 188-198

  Hsu, Chia Yang ^a,b   Lee, Yun Hsuan ^a,b   Huang, Yi Hsiang ^a,b   Hsia, Cheng Yuan ^a,b   Su, Chien Wei ^a,b   Lin, Han Chieh ^a,b   Lee, Rheun Chuan ^a,b   Chiou, Yi You ^a,b   Lee, Fa Yauh ^a,b   Huo, Teh Ia ^a,b   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Ascites; Hepatocellular carcinoma; Liver cirrhosis; MELD

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AKAIKE INFORMATION CRITERION; ARTICLE; ASCITES; BARCELONA CLINIC LIVER CANCER SCORING SYSTEM; CANCER INVASION; CANCER MORTALITY; CANCER OF THE LIVER ITALIAN PROGRAM SCORING SYSTEM; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; FACTORIAL ANALYSIS; FEMALE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPONATREMIA; JAPAN INTEGRATED SCORING SYSTEM; KIDNEY FAILURE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; SCORING SYSTEM; TAIPEI INTEGRATED SCORING SYSTEM; VASCULAR TUMOR;

EID: 84875236627     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-011-9338-z     Document Type: Article

References (39)

1. M Omata LA Lesmana R Tateishi, et al. 2010 Asian Pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma Hepatol Int 4 439 474 20827404 10.1007/s12072-010-9165-7
2. HB El-Serag JA Davila NJ Petersen, et al. 2003 The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update Ann Intern Med 139 817 823 14623619
3. JF Perz GL Armstrong LA Farrington, et al. 2006 The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J Hepatol 45 529 538 16879891 10.1016/j.jhep.2006.05.013
4. KP Moore GP Aithal 2006 Guidelines on the management of ascites in cirrhosis Gut 55 Suppl 6 vi1 vi12 16966752 10.1136/gut.2006.099580
5. P Ginès RW Schrier 2009 Renal failure in cirrhosis N Engl J Med 361 1279 1290 19776409 10.1056/NEJMra0809139
6. CY Hsu YH Huang CW Su, et al. 2010 Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization Liver Int 30 77 84 19818004 10.1111/j.1478-3231.2009.02128.x 1:CAS:528:DC%2BC3cXht1ajsrk%3D
7. TI Huo WY Lui JC Wu, et al. 2004 Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors, and association with intrahepatic tumor recurrence World J Surg 28 258 262 14961198 10.1007/s00268-003-7182-6
8. The Cancer of the Liver Italian Program (CLIP) Investigators 2000 Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma Hepatology 31 840 845 10.1053/he.2000.5628
9. J Bruix M Sherman 2005 Management of hepatocellular carcinoma Hepatology 42 1208 1236 16250051 10.1002/hep.20933
10. M Kudo H Chung S Haji, et al. 2004 Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score Hepatology 40 1396 1405 15565571 10.1002/hep.20486
11. CY Hsu YH Huang CY Hsia, et al. 2010 A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System J Hepatol 53 108 117 20451283 10.1016/j.jhep.2010.01.038
12. J Bruix M Sherman JM Llovet, et al. 2001 Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 421 430 11592607 10.1016/S0168-8278(01)00130-1 1:STN:280:DC%2BD3MrksFCmtg%3D%3D
13. BF Grant MC Dufour TC Harford 1988 Epidemiology of alcoholic liver disease Semin Liver Dis 8 12 25 3283941 10.1055/s-2008-1040525 1:STN:280:DyaL1c3gsV2ntg%3D%3D
14. European Association for the Study of the Liver 2010 EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis J Hepatol 53 397 417 10.1016/j.jhep.2010.05.004
15. J Bosch JC García-Pagán 2000 Complications of cirrhosis. I. Portal hypertension J Hepatol 32 Suppl 1 141 156 10728801 10.1016/S0168- 8278(00)80422-5 1:CAS:528:DC%2BD3cXkslylsbs%3D
16. G Garcia-Tsao 2001 Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis Gastroenterology 120 726 748 11179247 10.1053/gast.2001.22580 1:CAS:528:DC%2BD3MXhvFKnt78%3D
17. MM Oken RH Creech DC Tormey, et al. 1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 649 655 7165009 10.1097/00000421-198212000-00014 1:STN:280:DyaL3s7kvFOgsw%3D%3D
18. TA Gonwa L Jennings ML Mai, et al. 2004 Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations Liver Transpl 10 301 309 14762871 10.1002/lt.20017
19. EJ Lamb CR Tomson PJ Roderick 2005 Estimating kidney function in adults using formulae Ann Clin Biochem 42 321 345 16168188 10.1258/0004563054889936
20. V Mazzaferro E Regalia R Doci, et al. 1996 Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 693 699 8594428 10.1056/NEJM199603143341104 1:STN:280: DyaK287nsFWltw%3D%3D
21. TI Huo HC Lin YH Huang, et al. 2006 The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy Cancer 107 141 148 16708358 10.1002/cncr.21972
22. TI Huo YH Huang HC Lin, et al. 2006 Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy Am J Gastroenterol 101 975 982 16573785 10.1111/j.1572-0241.2006.00462.x
23. CY Hsu CY Hsia YH Huang, et al. 2010 Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models Cancer 116 3006 3014 20564406 10.1002/cncr.25044
24. DW Hosmer T Hosmer S Le Cessie, et al. 1997 A comparison of goodness-of-fit tests for the logistic regression model Stat Med 16 965 980 9160492 10.1002/(SICI)1097-0258(19970515)16:9<965::AID-SIM509>3.0.CO;2-O 1:STN:280:DyaK2szgsVaiuw%3D%3D
25. AR Feinstein 1972 Clinical biostatistics. XVI. The process of prognostic stratification Clin Pharmacol Ther 13 609 624 5042374 1:STN:280: DyaE383jtFSlug%3D%3D
26. JD Yang WR Kim R Coelho, et al. 2011 Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma Clin Gastroenterol Hepatol 9 64 70 20831903 10.1016/j.cgh.2010.08.019
27. M Casado J Bosch JC García-Pagán, et al. 1998 Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings Gastroenterology 114 1296 1303 9609767 10.1016/S0016- 5085(98)70436-6 1:STN:280:DyaK1c3ot1elug%3D%3D
28. HC Huang FY Lee TI Huo 2009 Major adverse events, pretransplant assessment and outcome prediction J Gastroenterol Hepatol 24 1716 1724 20136958 10.1111/j.1440-1746.2009.06025.x
29. SW Biggins WR Kim NA Terrault, et al. 2006 Evidence-based incorporation of serum sodium concentration into MELD Gastroenterology 130 1652 1660 16697729 10.1053/j.gastro.2006.02.010
30. WR Kim SW Biggins WK Kremers, et al. 2008 Hyponatremia and mortality among patients on the liver-transplant waiting list N Engl J Med 359 1018 1026 18768945 10.1056/NEJMoa0801209 1:CAS:528:DC%2BD1cXhtVymurbF
31. CY Hsu YH Huang CW Su, et al. 2010 Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency J Clin Gastroenterol 44 e171 e177 20048685
32. P Tangkijvanich N Anukulkarnkusol P Suwangool, et al. 2000 Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels J Clin Gastroenterol 31 302 308 11129271 10.1097/00004836-200012000-00007 1:STN:280:DC%2BD3M7ns1WjsQ%3D%3D
33. TI Huo CY Hsu YH Huang, et al. 2010 Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy BMC Gastroenterol 10 146 21194431 10.1186/1471-230X-10-146
34. TI Huo CY Hsu YH Huang, et al. 2010 Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma Liver Int 30 198 207 19849777 10.1111/j.1478-3231. 2009.02143.x 1:CAS:528:DC%2BC3cXhslWhtbs%3D
35. TI Huo YH Huang JC Wu 2005 Percutaneous ablation therapy for hepatocellular carcinoma: current practice and future perspectives J Chin Med Assoc 68 155 159 15850062 10.1016/S1726-4901(09)70239-4
36. IF Hsin CY Hsu HC Huang, et al. 2011 Incidence, risk factors and prognostic impact of liver failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization J Clin Gastroenterol 45 556 562 21666547 10.1097/MCG.0b013e318210ff17 1:CAS:528:DC%2BC3MXntlGns7k%3D
37. YJ Tsai CY Hsu YH Huang, et al. 2011 Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma Hepatol Int 5 975 984 10.1007/s12072-011-9276-9
38. G Cabibbo M Enea M Attanasio, et al. 2010 A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma Hepatology 51 1274 1283 20112254 10.1002/hep.23485
39. T Yau TJ Yao P Chan, et al. 2008 A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials Cancer 113 2742 2751 18853421 10.1002/cncr.23878